I do not consider APBI in patients who have received neoadjuvant chemotherapy. While I am aware that some do, I do have concern regarding encompassing volume at risk. With more patients receiving neoadjuvant endocrine therapy, this is also an area where we don't have great data. I have not traditio...

Interesting question. However, I am not offering APBI after neoadjuvant chemotherapy. This situation would pose multiple difficulties, as the criteria for APBI eligibility are currently based upon pathologic factors in the absence of neoadjuvant chemotherapy. In addition, many of the patients receiv...

There is no data in this setting, and not knowing what the real target is could lead to higher recurrence, unless done in a clinical trial setting.